Lead Sponsor

Boehringer Ingelheim

Age

40 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Written informed consent prior to participation
•2. Female and male patients = 40 years of age
•3. Patients diagnosed with COPD and requiring long-acting dual bronchodilation (LAMA + LABA) treatment according to approved Spiolto® Respimat® SmPC and therapeutic plan recommendation

•1. Patients with contraindications according to Spiolto® Respimat® Summary of Product Characteristics (SmPC)
•2. Patients who have been treated with a LABA/LAMA combination (free and fixed dose) in the previous 6 months
•3. Patients continuing LABA-Inhalative Corticosteroids (ICS) treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta-agonists
•4. Patients for whom further follow-up is not possible at the enrolling site during the planned study period of approx. 6 weeks
•5. Pregnancy and lactation
•6. Patients currently listed for lung transplantation
•7. Current participation in any clinical trial or any other non-interventional study of a drug or device